Skip to content
Open access

Outcomes of Continuous Infusion Versus Intermittent Bolus Injection of Furosemide in Patients with Acute Decompensated Heart Failure (ADHF): A Prospective Observational Comparative Study

2026 · International journal of research and innovation in social science · Vol 10, pp. 4192-4205 · 0 citations

TL;DR

Both dosing methods were effective in relieving symptoms of acute decompensated heart failure: Continuous infusion produced greater diuresis, while bolus dosing also remained effective.

Abstract

Acute decompensated heart failure is a frequent cause of hospital admission and is commonly managed with intravenous loop diuretics. Furosemide is usually given either as intermittent bolus doses or as a continuous infusion, but the optimal method of administration remains uncertain in routine clinical practice. The study included forty patients (n=40, 20 per group) diagnosed with heart failure, encompassing both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). Patients presenting with symptoms like dyspnea or edema were excluded if their systolic blood pressure fell below 90 mm Hg or if their condition was critically ill. A total of 40 patients with acute decompensated heart failure were included in the study, with 20 patients in each treatment group. Baseline clinical and laboratory parameters were comparable between the groups. Urine output during the three-day treatment period was higher in patients treated with continuous furosemide infusion than in those who received bolus doses (p = 0.037). Serum creatinine, sodium, and potassium levels showed no significant differences between the two groups. Vital signs remained stable in both treatment arms throughout the study period. Both dosing methods were effective in relieving symptoms of acute decompensated heart failure. Continuous infusion produced greater diuresis, while bolus dosing also remained effective. The choice of treatment should be based on the patient’s clinical condition. Further studies with larger samples are required to assess long-term outcomes.

Read PDF

Similar papers

Sep 2026

Hypertonic saline and high-dose furosemide in very elderly patients hospitalized for acute heart failure: A real-world cohort study.

BACKGROUND The combination of hypertonic saline solution (HSS) and high-dose furosemide may enhance diuretic response in acute heart failure (AHF), but evidence in real-world populations, particularly very elderly patients admitted to internal medicine wards, remains limited. METHODS Retrospective, single-center, unc...

G. Ropero-Luis, M. E. Carmona-Moreno, M. Melgar-Velasco et al. · 2 citations
Open access Oct 2026

Ambulatory milrinone in advanced heart failure: a single-center comparison of continuous and intermittent infusion strategies

Outpatient management of advanced heart failure is challenging. Intravenous inotropes, administered intermittently or continuously, may serve as destination therapy or as a bridge to definitive treatment in selected patients. This study aims to evaluate the efficacy and safety of ambulatory milrinone in ad...

A. Rioux, É. Voisine, S. Berube et al. · 0 citations
Open access Oct 2026

The ACETAZ-HF trial: intravenous furosemide plus oral acetazolamide for rapid decongestion in acute HFrEF and sustained outpatient benefit

Rapid and sustained decongestion in acute heart failure with reduced ejection fraction (HFrEF) remains a therapeutic challenge, particularly in patients with diuretic resistance. Sequential nephron blockade with acetazolamide may enhance decongestion during hospitalization and, when continued intermittently after...

R. Sabido, S. Ramos, M. Lagunas et al. · 0 citations
Open access Oct 2026

Ivabradine for hemodynamic optimization and catecholamine weaning in cardiogenic shock: a retrospective cohort study

Heart rate control may represent a key therapeutic target in cardiogenic shock (CS), particularly in patients who experience failure of catecholamine weaning. Ivabradine, a selective sinus node inhibitor, could improve ventriculo-arterial coupling and hemodynamic stability; however, clinical data in this setting...

O. Haddar, S. Charfeddine, Y. Kobbi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.